Special Instructions
Individuals experiencing chronic fatigue, frequent infections, or slow wound healing People managing chronic conditions like diabetes, cardiovascular disease, or autoimmune disorders Athletes and active individuals seeking to optimize performance and recovery Those following restrictive diets (vegetarian, vegan, gluten-free) or with digestive issues Adults over 50 concerned about age-related nutrient absorption changes Anyone taking medications that may affect nutrient absorption or utilization How It Works Just 3 Steps Schedule your blood draw at home or at a convenient lab location Provide 2 yellow ACD tubes of blood - no fasting or special preparation needed Receive comprehensive results in your secure portal within 14-21 days Note: Once your specimen has been mailed to the laboratory, your order cannot be canceled or refunded

What the Research Does NOT Yet Support - There are currently no published randomised controlled trials (RCTs) in humans for BPC-157 - Human pharmacokinetic data (how it is absorbed, distributed, metabolised, and excreted) is limited - Optimal dosing, route of administration, and treatment duration have not been established clinically - Long-term safety data in humans is absent - Regulatory approval from the TGA, FDA, or EMA has not been granted for any therapeutic indication TB-500: Evidence Overview What the Research Supports TB-500 / Thymosin Beta-4 has somewhat more human-facing research, though still predominantly preclinical: Phase I and II clinical trials have investigated Thymosin Beta-4 (the native peptide) in cardiac repair following myocardial infarction, with promising safety profiles Wound healing applications have been explored in clinical settings, particularly for chronic non-healing wounds and dry eye disease Robust animal evidence supports its role in reducing inflammation, supporting angiogenesis, and promoting tissue regeneration The native peptide (T4) has demonstrated cardioprotective effects in animal models of heart failure and ischaemia What the Research Does NOT Yet Support TB-500 is a synthetic fragment of T4 it is not identical to the native peptide, and extrapolating human clinical data from T4 studies directly to TB-500 may not be valid No approved therapeutic indications exist for TB-500 specifically Comparative efficacy versus established treatments has not been studied The long-term effects of exogenous peptide administration on endogenous thymosin beta-4 regulation are unknown Potential Benefits: A Summary Based on the available (predominantly preclinical) literature, the following potential benefits have been identified: Risks & Safety Considerations Known & Reported Side Effects Because large-scale human trials are lacking, our understanding of the side effect profile is limited

Cu-GHK helps lay the foundation for: Smoother, firmer skin Faster tissue recovery Improved resilience and repair Renewed vitality over time DrWells GHK-Cu Injections Support aging at the cellular level with DWells Cu-GHK: a potent copper-binding peptide that works deep within the body to restore balance, structure, and strength
ConA, concanavalin A